S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
NASDAQ:RLYB

Rallybio Stock Forecast, Price & News

$13.22
+0.07 (+0.53%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.75
$13.65
50-Day Range
$10.83
$19.91
52-Week Range
$10.05
$25.78
Volume
26,329 shs
Average Volume
111,726 shs
Market Capitalization
$424.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive RLYB News and Ratings via Email

Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter.


Rallybio logo

About Rallybio

Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RLYB
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$5.80 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$424.76 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/09/2022

MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

948th out of 1,392 stocks

Pharmaceutical Preparations Industry

448th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Rallybio (NASDAQ:RLYB) Frequently Asked Questions

Is Rallybio a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rallybio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rallybio stock.
View analyst ratings for Rallybio
or view top-rated stocks.

Are investors shorting Rallybio?

Rallybio saw a increase in short interest during the month of October. As of October 29th, there was short interest totaling 455,600 shares, an increase of 24.5% from the October 14th total of 365,800 shares. Based on an average trading volume of 92,500 shares, the short-interest ratio is presently 4.9 days. Currently, 3.3% of the shares of the stock are short sold.
View Rallybio's Short Interest
.

When is Rallybio's next earnings date?

Rallybio is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Rallybio
.

How were Rallybio's earnings last quarter?

Rallybio Corp (NASDAQ:RLYB) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.52.
View Rallybio's earnings history
.

What price target have analysts set for RLYB?

3 equities research analysts have issued twelve-month price objectives for Rallybio's stock. Their forecasts range from $20.00 to $40.00. On average, they expect Rallybio's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 126.9% from the stock's current price.
View analysts' price targets for Rallybio
or view top-rated stocks among Wall Street analysts.

When did Rallybio IPO?

(RLYB) raised $80 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 5,750,000 shares at $13.00-$15.00 per share.

What is Rallybio's stock symbol?

Rallybio trades on the NASDAQ under the ticker symbol "RLYB."

When does Rallybio's lock-up period expire?

Rallybio's lock-up period expires on Tuesday, January 25th. Rallybio had issued 6,200,000 shares in its IPO on July 29th. The total size of the offering was $80,600,000 based on an initial share price of $13.00. After the expiration of Rallybio's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Who are Rallybio's major shareholders?

Rallybio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Viking Global Investors LP (13.06%), New Leaf Venture Partners L.L.C. (7.16%), Sectoral Asset Management Inc (1.64%), Laurion Capital Management LP (1.24%), BlackRock Inc. (0.91%) and Geode Capital Management LLC (0.22%).

Which institutional investors are buying Rallybio stock?

RLYB stock was acquired by a variety of institutional investors in the last quarter, including Viking Global Investors LP, New Leaf Venture Partners L.L.C., Sectoral Asset Management Inc, Laurion Capital Management LP, BlackRock Inc., Geode Capital Management LLC, Millennium Management LLC, and Bank of New York Mellon Corp.

How do I buy shares of Rallybio?

Shares of RLYB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rallybio's stock price today?

One share of RLYB stock can currently be purchased for approximately $13.22.

How much money does Rallybio make?

Rallybio has a market capitalization of $424.76 million.

How many employees does Rallybio have?

Rallybio employs 2,021 workers across the globe.

What is Rallybio's official website?

The official website for Rallybio is www.rallybio.com.

How can I contact Rallybio?

The company can be reached via phone at 203-859-3820 or via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.